| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/11/2001 | WO2001074345A2 Isoflavones for treatment of obesity |
| 10/11/2001 | WO2001074344A2 Small organic molecule regulators of cell proliferation |
| 10/11/2001 | WO2001074343A2 Method for the treatment of dermal lesions caused by envenomation |
| 10/11/2001 | WO2001074341A2 Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant |
| 10/11/2001 | WO2001074340A2 Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug |
| 10/11/2001 | WO2001074339A2 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
| 10/11/2001 | WO2001074337A1 System for transporting active substances in a biological system |
| 10/11/2001 | WO2001074335A1 Pharmaceutical kit comprising midodrine as an active drug substance |
| 10/11/2001 | WO2001074334A1 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine |
| 10/11/2001 | WO2001074333A1 D and l etherlipid stereoisomers and liposomes |
| 10/11/2001 | WO2001074332A1 Pharmaceutical preparations and their manufacture |
| 10/11/2001 | WO2001074330A2 Method for treating dry eye |
| 10/11/2001 | WO2001074329A2 Sustained release beadlets containing stavudine |
| 10/11/2001 | WO2001074317A1 Methods of modulating hair growth |
| 10/11/2001 | WO2001074315A2 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| 10/11/2001 | WO2001074314A2 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| 10/11/2001 | WO2001074313A2 Compositions and methods for treating hair loss using c16 - c20 aromatic tetrahydro prostaglandins |
| 10/11/2001 | WO2001074307A2 Compositions and methods for treating hair loss using oximyl- and hydroxylamino- prostaglandins |
| 10/11/2001 | WO2001074296A2 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
| 10/11/2001 | WO2001074279A1 Topical compositions containing prostaglandin e¿1? |
| 10/11/2001 | WO2001074180A1 Nutritional supplements for stimulating bone growth |
| 10/11/2001 | WO2001074173A1 Supplementation of equine feedstuffs |
| 10/11/2001 | WO2001074165A1 Chitosan formulation with azelaic acid and other actives for the treatment of acne |
| 10/11/2001 | WO2001052833A8 Compositions for delivery of a cortisol antagonist |
| 10/11/2001 | WO2001049317A3 Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen |
| 10/11/2001 | WO2001048190A8 Therapeutic uses of lna-modified oligonucleotides |
| 10/11/2001 | WO2001034572A3 Carboxamide-substituted benzimidazol derivatives, method for the production thereof and their use as tryptase inhibitors |
| 10/11/2001 | WO2001031003B1 Cloning, expression and characterisation of a gene expressed in tumour cells and involved in the regulation of the immune response |
| 10/11/2001 | WO2001028566B1 Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia |
| 10/11/2001 | WO2001028556A3 Compositions for prevention and treatment of cold and influenza-like symptoms and their methods of use |
| 10/11/2001 | WO2001027119A3 Substance library containing bicyclic imidazo-5-yl-amines and/or bicyclic imidazo-3-yl-amines |
| 10/11/2001 | WO2001026621A3 Orally distintegrating composition comprising mirtazapine |
| 10/11/2001 | WO2001025269A3 Human g-protein coupled receptor |
| 10/11/2001 | WO2001025210A3 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands |
| 10/11/2001 | WO2001024763A3 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 10/11/2001 | WO2001022956A3 NOVEL COMBINATION OF LOTEPREDNOL AND β2-ADRENOCEPTOR AGONISTS |
| 10/11/2001 | WO2001022951A3 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis |
| 10/11/2001 | WO2001021799B1 Traf4 associated cell cycle proteins, compositions and methods of use |
| 10/11/2001 | WO2001021587A3 Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors |
| 10/11/2001 | WO2001021585A3 Bis(1-aziridino-1-hydroxyiminomethyl)-derivatives, method for the production thereof and use thereof as anti-tumoral agents |
| 10/11/2001 | WO2001021153A3 Pharmaceutical gel containing active substances |
| 10/11/2001 | WO2001020025A3 Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications |
| 10/11/2001 | WO2001019826A3 Triazolopyrimidine derivatives |
| 10/11/2001 | WO2001017518A3 Method of treatment of influenza |
| 10/11/2001 | WO2001015777A8 Pulmonary-administration of mineral ascorbates |
| 10/11/2001 | WO2001015692A8 Methods and compositions for selective cancer chemotherapy |
| 10/11/2001 | WO2001012579A3 New stilbenes with vascular damaging activity |
| 10/11/2001 | WO2001012264A3 Topical azathioprine for the treatment of oral autoimmune diseases |
| 10/11/2001 | WO2001002377A9 Telomerase inhibitors and methods of their use |
| 10/11/2001 | WO2000076556A3 High dose radionuclide complexes for bone marrow suppression |
| 10/11/2001 | WO2000064421A3 Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients |
| 10/11/2001 | WO2000062736A3 Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion |
| 10/11/2001 | WO2000051596A9 Antithrombotic use of glycine betaine |
| 10/11/2001 | WO2000049413A9 Rapid assay for arthropod-borne disease vectors and pathogens |
| 10/11/2001 | WO2000048606A9 Compositions and methods for use in targeting vascular destruction |
| 10/11/2001 | WO2000042058A9 Steroid derived antibiotics |
| 10/11/2001 | WO2000041690A9 Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism |
| 10/11/2001 | WO2000041472A3 Binding partners for 5-ht5-receptors for the treatment of migraine |
| 10/11/2001 | WO2000038669A3 Use of naloxone for preventing and treating the degeneration of neurons |
| 10/11/2001 | WO2000030628A3 Method of inhibiting angiogenesis |
| 10/11/2001 | WO2000017176A3 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments |
| 10/11/2001 | WO2000016763A3 Antimalarial agents |
| 10/11/2001 | US20010029399 Poly (vinyl alcohol) hydrogel |
| 10/11/2001 | US20010029357 Enhanced intra vaginal devices |
| 10/11/2001 | US20010029351 Drug combinations and delivery devices for the prevention and treatment of vascular disease |
| 10/11/2001 | US20010029304 Cyclopentane heptan (ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| 10/11/2001 | US20010029303 Total synthesis of antitumor acylfulvenes |
| 10/11/2001 | US20010029270 Aqueous solution |
| 10/11/2001 | US20010029269 Non-steroidal antiinflammatory agent |
| 10/11/2001 | US20010029268 Topical application |
| 10/11/2001 | US20010029267 Infant formula and methods of improving infant stool patterns |
| 10/11/2001 | US20010029266 Skin disorders, mucous membranes, keratin fibers |
| 10/11/2001 | US20010029265 Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives |
| 10/11/2001 | US20010029264 In mixture with vitamin e, dimethylisosorbide, citric acid and polyoxyethylene glycol |
| 10/11/2001 | US20010029263 Alopecia |
| 10/11/2001 | US20010029262 Method of treatment or prophylaxis |
| 10/11/2001 | US20010029261 Alopecia therapy |
| 10/11/2001 | US20010029260 Methods for treating hypertension and angina using salts of optically pure (-) amplodipine |
| 10/11/2001 | US20010029258 Partially saturated calcium channel blockers |
| 10/11/2001 | US20010029257 Transdermal adminitsering mixture of amine compound in carrier |
| 10/11/2001 | US20010029255 Use of an H+, K+-ATPase inhibitor in the treatment of widal's syndrome |
| 10/11/2001 | US20010029253 Composition for external application containing a beta-1,6-branched-beta-1,3-glucan |
| 10/11/2001 | US20010029252 Prevent brain and nervous system damage; anemia |
| 10/11/2001 | US20010029251 Administering cytomegalo virus protein |
| 10/11/2001 | US20010029250 Antiinflammatory agents; anticarcinogenic agents |
| 10/11/2001 | US20010029249 Adenovirus comprising a gene coding for glutathione peroxidase |
| 10/11/2001 | US20010029248 Composition for and method of reducing low density lipoprotein cholesterol concentration |
| 10/11/2001 | US20010029247 Use of a- alkylglucosides and a-alkylglucoside esters as anti-microbial emulsifying agents |
| 10/11/2001 | US20010029244 Method for treating or preventing psychosomatic and psychoimmunologic disorders |
| 10/11/2001 | US20010029040 Agent for gene therapy of dilated cardomyopathy |
| 10/11/2001 | US20010029020 In vitro determination of metastatic stomach, esophageal, and colorectal cancer from sampling cells outside of the colorectal track for gene transcript or protein |
| 10/11/2001 | US20010029019 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 10/11/2001 | US20010028897 Mixture of adrenergic blocking agent and plant extract of Saw Palmetto |
| 10/11/2001 | US20010028896 Controlled release lipoic acid |
| 10/11/2001 | US20010028895 Decreasing amyloid protein |
| 10/11/2001 | US20010028889 Topical |
| 10/11/2001 | US20010028888 Cosmetic or dermatological light protection agent preparations |
| 10/11/2001 | DE10110455A1 Sensitizer for tumor treatment contains a xanthene dye structure and a structure with at least one hydrophilic group and at least one lipophilic group bound to one and the same carbon atom in the molecule |
| 10/11/2001 | DE10017480A1 Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren Use of substances that act as MEK inhibitor for the manufacture of a Arneimittels against DNA and RNA viruses |
| 10/11/2001 | DE10017102A1 Verfahren zur Herstellung von festen Kreatin-Dosierungsformen und dadurch erhältliche Dosierungsformen A process for producing solid creatine dosage forms and dosage forms obtainable thereby |